Total mood scores for both groups were similar at baseline but was significantly different at the end of the study, with the PEA group decreasing and the placebo group increasing. Evening VAS scores were significantly reduced from baseline in both the LipiSperse® and placebo groups from day 3. VAS scores were significantly lower in the LipiSperse® group compared to the placebo group on day 14 (P<0.05). Morning VAS scores were significantly reduced from baseline in the LipiSperse® and placebo groups from day 3 and 4 respectively. VAS pain scores reduced over the 2 weeks of treatment in both groups. The primary outcome was a self-assessed reduction in pain as assessed by a visual analogue scale (VAS) for pain, completed in the morning and evening. 74 participants that received either LipiSperse® (n=35) or a placebo (n=39) daily for 2 weeks completed this study.

A randomised, double blind, placebo-controlled study on adults reporting joint pain. This study aimed to assess the efficacy of palmitoylethanolamide (LipiSperse®), for alleviating joint pain and improving quality of life in adults. Palmitoylethanolamide (PEA) is an endogenous saturated fatty acid derivative that down-regulates multiple proinflammatory and nociceptive pathways and known to inhibit mast and glial cell activity. A commonality of all joint pain is the existence of inflammation.

Double blind study